Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 161

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9B
Chunk 161
---
 activities and operations include a project funded by the U.S. National Institute on Aging, an institute of the U.S.
National Institutes of Health (“NIH”): Safety and Pharmacokinetics of JOTROL for Alzheimer’s Disease, Federal Award
Identification Number R44AG067907-01A1 (the “Award”). The project encompassed a Phase 1 dose finding pharmacokinetics (“PK”)
study which was completed before December 31, 2021. The award end date was May 31, 2022. This Phase 1 PK study will be homogeneous for
all indications where JOTROL will be used in Phase II and Phase III clinical trials.

On
January 9, 2020, the Company effected a three-for-one (3:1) forward stock split whereby the Company (i) increased the number of authorized
shares of common stock, $0.0001 par value per share, to 25,000,000 from 5,000,000 and (ii) increased by a ratio of three-for-one (3:1)
the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the forward stock split were
made to the Company’s outstanding stock options, warrants and equity incentive plans.

On
November 11, 2021, the Company increased the number of authorized shares of common stock, $0.0001 par value per share, to 45,000,000
from 25,000,000.

On
January 25, 2022, the Company effected a one-for-two (1:2) reverse stock split whereby the Company (i) decreased the number of issued
and outstanding shares of common stock, $0.0001 per share, from 13,076,608 to 6,538,304 and (ii) decreased by a ratio of one-for two
(1:2) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split
were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts
have been retroactively adjusted as of the earliest period presented in the financial statements to reflect the reverse stock split.

On
June 14, 2024, the Company increased the number of authorized shares of common stock, $0.0001 par value per share, to 125,000,000 from
45,000,000.

On
June